Evidence map›Paper›PMID 20970954›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2010

Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells.

Omana P Mathew, Kasturi Ranganna, Frank M Yatsu

Open access · greenAbstract read
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Gut Microbiota as a Mediator of Dietary Salt Effects on Blood Pressure.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Recent Updates on Epigenetic-Based Pharmacotherapy for Atherosclerosis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Omana P MathewDepartment of Pharmaceutical Sciences, College of Pharmacy, Texas Southern University, 3100, Cleburne Street, Houston, Texas 77004, USA.
Kasturi Ranganna
Frank M Yatsu
Texas Southern University · USThe University of Texas Health Science Center at Houston · US

Funding

TISSUE CULTURE FACILITY DVMT FOR HYPERTENSION, DIABETES, TOXICOLOGY &AIDS RESG12RR003045 · NCRR · TEXAS SOUTHERN UNIVERSITY · PI HAYES, BARBARA ELAINE · 1986 to 2011
$13.6M
ADDITION AND RENOVATION TO GRAY HALLC06RR012537 · NCRR · TEXAS SOUTHERN UNIVERSITY · PI HAYES, BARBARA ELAINE · 1997 to 1997
–
NCRR NIH HHS C06 RR012537NCRR NIH HHS C06RR012537-01NCRR NIH HHS G12 RR003045NCRR NIH HHS G12RR0345
6 · The paper itself

Abstract

HDACs and HATs regulate histone acetylation, an epigenetic modification that controls chromatin structure and through it, gene expression. Butyrate, a dietary HDAC inhibitor, inhibits VSMC proliferation, a crucial factor in atherogenesis, and the principle mechanism in arterial and in-stent restenosis. Here, the link between antiproliferation action of butyrate and the portraits of global covalent modifications of histone H3 that it induces are characterized to understand the mechanics of butyrate-arrested VSMC proliferation. Analysis of histone H3 modifications specific to butyrate arrested VSMC proliferation display induction of histone H3-Lysine9 acetylation, inhibition of histone H3-Serine10 phosphorylation, reduction of histone H3-Lysine9 dimethylation and stimulation of histone H3-Lysine4 di-methylation, which is linked to transcriptional activation, cell cycle/mitosis, transcriptional suppression and activation, respectively. Conversely, untreated VSMCs exhibit inhibition of H3-Lysine9 acetylation, induction of H3-Serine10 phosphorylation, stimulation of H3-Lysine9 di-methylation and reduction in H3-Lysine4 di-methylation. Butyrate's cooperative effects on H3-Lysine9 acetylation and H3-Serine10 phosphorylation, and contrasting effects on di-methylation of H3-Lysine9 and H3-Lysine4 suggests that the interplay between these site-specific modifications cause distinct chromatin alterations that allow cyclin D1 and D3 induction, G1-specific cdk4, cdk6 and cdk2 downregulation, and upregulation of cdk inhibitors, p15INK4b and p21Cip1. Regardless of butyrate's effect on D-type cyclins, downregulation of G1-specific cdks and upregulation of cdk inhibitors by butyrate prevents cell cycle progression by failing to inactivate Rb. Overall, through chromatin remodeling, butyrate appears to differentially alter G1-specific cell cycle proteins to ensure proliferation arrest of VSMCs, a crucial cellular component of blood vessel wall.

Indexed as

AcetylationAnimalsAtherosclerosisButyratesCell CycleCell Cycle ProteinsCell ProliferationCells, CulturedChromatinCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent KinasesCyclinsDown-RegulationG1 PhaseGene Expression RegulationButyratesCell Cycle ProteinsChromatinCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent KinasesCyclinsHistone Deacetylase InhibitorsHistonesRetinoblastoma Protein

Identifiers

PMID20970954
PMCPMC2997917
OpenAlexW1983403685

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.